International Medical Center of Biomaterials Processing and Cryostorage (MOEX:GEMA)

MOEX:GEMA Ratios and Metrics

Market cap in millions RUB. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 7, 2022	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	10,033	10,033	10,033	10,033	14,915	10,302
Market Cap Growth	-	-	-	-32.73%	44.78%	-9.39%
Enterprise Value	10,029	10,045	10,171	10,076	14,939	10,314
Last Close Price	672.00	672.00	672.00	672.00	950.69	580.21
PE Ratio	66.35	66.35	79.77	102.20	98.94	83.91
PS Ratio	27.29	28.78	35.39	39.40	56.10	42.46
PB Ratio	32.40	33.02	22.76	67.45	66.00	49.06
P/TBV Ratio	42.86	44.55	28.18	172.94	74.92	58.09
P/FCF Ratio	40.74	42.42	47.87	43.28	62.19	77.89
P/OCF Ratio	39.20	40.52	44.84	41.61	61.00	76.47
EV/Sales Ratio	27.28	28.82	35.88	39.56	56.19	42.51
EV/EBITDA Ratio	51.02	53.88	64.52	70.75	105.17	69.54
EV/EBIT Ratio	55.32	56.39	68.10	72.70	108.33	72.70
EV/FCF Ratio	40.72	42.47	48.53	43.46	62.29	77.98
Debt / Equity Ratio	0.79	0.79	0.59	1.76	0.24	0.28
Debt / EBITDA Ratio	1.29	1.29	1.62	1.80	0.39	0.39
Debt / FCF Ratio	1.01	1.01	1.24	1.13	0.23	0.45
Asset Turnover	0.28	0.28	0.26	0.32	0.39	0.40
Inventory Turnover	8.82	8.82	9.88	10.81	15.68	10.19
Quick Ratio	1.88	1.88	1.24	0.83	3.53	0.97
Current Ratio	1.92	1.92	1.36	0.90	3.58	1.02
Return on Equity (ROE)	40.61%	40.61%	42.66%	52.39%	59.26%	60.46%
Return on Assets (ROA)	8.86%	8.86%	8.63%	10.95%	12.77%	14.58%
Return on Capital (ROIC)	17.89%	17.89%	16.81%	25.06%	31.32%	35.63%
Return on Capital Employed (ROCE)	17.00%	17.00%	13.60%	18.90%	26.00%	28.90%
Earnings Yield	1.51%	1.51%	1.25%	0.98%	0.87%	1.19%
FCF Yield	2.45%	2.36%	2.09%	2.31%	1.61%	1.28%
Dividend Yield	1.29%	-	0.95%	1.19%	0.91%	-
Payout Ratio	99.74%	101.44%	97.58%	143.69%	116.27%	69.31%
Buyback Yield / Dilution	-	-	-	0.00%	-0.00%	-11.11%
Total Shareholder Return	1.29%	-	0.95%	1.20%	0.91%	-11.11%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.